Exelixis releases positive results from Phase II trial of lung cancer drug cabozantinib

… treat EGFR wild-type non-small cell lung cancer (NSCLC). Conducted by the ECOG-ACRIN … the availability of new therapies, lung cancer continues to pose significant clinical … of cabozantinib in non-small cell lung cancer." Exelixis president and chief …